vitiligo white spot disease
Conditions
Interventions
NB UVB phototherapy twice a week for twelve months with either topical use of
fluticasone proprionate or NB UVB phototherapy alone
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with active vitiligo, eligible for NB-UVB phototherapy; Subjects attending the outpatient department of the SNIP; Adult patients: * 18 years; Subject is willing and able to give written informed consent.
Exclusion criteria
Exclusion criteria: With a personal or a family history of skin cancer (non-melanoma skin cancer: first degree family members, melanoma: any family member) With a personal history of photosensitivity and/or phototoxicity disorders With skin type I (according to Fitzpatrick classification I-VI) Who are pregnant Who are taking medications known to cause photosensitivity and/or phototoxicity and chronic or very frequent use of any medication that can influence the UVB response (eg. tetracycline, retinoids, sulfonamids, psoralens, NSAID*s) With other skin diseases that would impair evaluation of repigmentation, such as psoriasis and eczema. Who are not able to have 2 times weekly NB-UVB phototherapy With local immunosuppressive treatment or 6 weeks prior to enrolment. For these patients a washout period of 6 weeks will be required.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The onset and degree of pigment spread is assessed by digital image analysis, and the patients and doctors satisfaction will be evaluated | — |
Secondary
| Measure | Time frame |
|---|---|
| - | — |
Countries
Netherlands
Outcome results
None listed